Author: Editor

Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about an Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.     Outline   Intent:   Entrectinib inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and has previously elicited profound [57.4 percent] and sustained [median duration of response (DoR) 10.4 months] responses in…

Gerard E Mullin, MD, MS, Associate Professor of Medicine at Johns Hopkins Medicine. In this video, he speaks about Study: Taller Adults May be at Increased Risk for Colorectal Cancer.   Outline   Origins:   The impact of anthropometric factors on colorectal neoplasia biology remains unknown. A comprehensive review and meta-analysis were performed to assess whether adult-attained height is independently linked with the risk of colon cancer or adenoma. Methods: From inception through August 2020, we searched MEDLINE, EMBASE, the Cochrane Library, and Web of Science for papers on the relationship between adult-attained height and colorectal cancer or adenoma. The…

Gerard E Mullin, MD, MS, Associate Professor of Medicine at Johns Hopkins Medicine. In this video, he speaks about Study: Taller Adults May be at Increased Risk for Colorectal Cancer.   Outline   Origins:   The impact of anthropometric factors on colorectal neoplasia biology remains unknown. A comprehensive review and meta-analysis were performed to assess whether adult-attained height is independently linked with the risk of colon cancer or adenoma. Methods: From inception through August 2020, we searched MEDLINE, EMBASE, the Cochrane Library, and Web of Science for papers on the relationship between adult-attained height and colorectal cancer or adenoma. The…

Jens Hillengass, MD, Ph.D., Chief of Myeloma, Professor of Oncology at Roswell Park Comprehensive Cancer Center. In this video, he speaks about Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.   Overview:   Symptomatic multiple myeloma is distinguished by osteolytic lesions (OL). The methods by which malignant plasma cells (PC) cause OL in one place while not causing bone damage in others despite thorough invasion remain unexplained. We present a prospective single-cell RNA sequencing (scRNA-seq) investigation of PC derived from random bone marrow aspirates (BM) and matched imaging-guided OL biopsies. Based on scRNA-seq analysis, we examined…

Prof. dr. Xavier Pivot, MD, Ph.D., Professor of Oncology, General Director of Paul Strauss anti-Cancer Center, Chairman of the Regional Cancer Institute at Institute De Cancerologie Stansbourg (iCANS). In this video, he speaks about the Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting.   Overview:   Importance HD201 is a biosimilar candidate to trastuzumab in the treatment of breast cancer.   The goal of this study was to evaluate the efficacy of HD201 to that of the comparator trastuzumab.   Design, environment, and participants:   This randomized clinical trial (TROIKA) recruited…

Prof. dr. Xavier Pivot, MD, Ph.D., Professor of Oncology, General Director of Paul Strauss anti-Cancer Center, Chairman of the Regional Cancer Institute at Institute De Cancerologie Stansbourg (iCANS). In this video, he speaks about the Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting.   Overview:   Importance HD201 is a biosimilar candidate to trastuzumab in the treatment of breast cancer.   The goal of this study was to evaluate the efficacy of HD201 to that of the comparator trastuzumab.   Design, environment, and participants:   This randomized clinical trial (TROIKA) recruited…

Constantinos Koumenis, Ph.D., BS, Richard H. Chamberlain Professor of Research Oncology, Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania. In this video, he speaks about Penn Medicine Awarded $12.3M NIH Grant to Study Ultra-Fast, High-Dose FLASH Radiation Therapy for Cancer.   Description in Detail:   The purpose of this clinical study is to evaluate the workflow feasibility of FLASH radiation treatment in a clinical setting, as well as the toxicities and pain alleviation when utilized to treat bone metastasis(-es) in the extremities (excluding feet, hands, wrists). FLASH radiotherapy has been found in preclinical experiments to cause less…

Constantinos Koumenis, Ph.D., BS, Richard H. Chamberlain Professor of Research Oncology, Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania. In this video, he speaks about Penn Medicine Awarded $12.3M NIH Grant to Study Ultra-Fast, High-Dose FLASH Radiation Therapy for Cancer.   Description in Detail:   The purpose of this clinical study is to evaluate the workflow feasibility of FLASH radiation treatment in a clinical setting, as well as the toxicities and pain alleviation when utilized to treat bone metastasis(-es) in the extremities (excluding feet, hands, wrists). FLASH radiotherapy has been found in preclinical experiments to cause less…

Philippe Bedard, MD is an Associate Professor of Medicine at the University of Toronto. He is a Staff Medical Oncologist in the Division of Medical Oncology and the Fellowship Director for the Bras Drug Development Program at the Princess Margaret Cancer Centre in Toronto. In this video, he speaks about the SABCS 2021 Abstract – Safety and Efficacy of INT230-6, a Potential First-in-Class Intratumoral Therapy, in Monotherapy and in Combination with Pembrolizumab: Results from the IT-01 Study KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Breast Cancer.     Description in detail:   INT230-6 is a fixed-ratio combination of…

Philippe Bedard, MD is an Associate Professor of Medicine at the University of Toronto. He is a Staff Medical Oncologist in the Division of Medical Oncology and the Fellowship Director for the Bras Drug Development Program at the Princess Margaret Cancer Centre in Toronto. In this video, he speaks about the SABCS 2021 Abstract – Safety and Efficacy of INT230-6, a Potential First-in-Class Intratumoral Therapy, in Monotherapy and in Combination with Pembrolizumab: Results from the IT-01 Study KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Breast Cancer.     Description in detail:   INT230-6 is a fixed-ratio combination of…

John H. Bushweller, Ph.D., Professor, Molecular Physiology and Biological Physics at the University of Virginia, Program Leader at UVA Cancer Center. In this video, he speaks about Surprise Discovery Suggests New Treatment for Deadly Lung Cancer.   An unexpected discovery at the University of Virginia Cancer Center has enabled scientists to prevent the progression of small-cell lung cancer in lab mice, and the surprising finding may pave the way for a new therapeutic method in humans.   The researchers, led by UVA’s Kwon-Sik Park and John H. Bushweller, wanted to know how a mutation in the EP300 gene contributes to…

John H. Bushweller, Ph.D., Professor, Molecular Physiology and Biological Physics at the University of Virginia, Program Leader at UVA Cancer Center. In this video, he speaks about Surprise Discovery Suggests New Treatment for Deadly Lung Cancer.   An unexpected discovery at the University of Virginia Cancer Center has enabled scientists to prevent the progression of small-cell lung cancer in lab mice, and the surprising finding may pave the way for a new therapeutic method in humans.   The researchers, led by UVA’s Kwon-Sik Park and John H. Bushweller, wanted to know how a mutation in the EP300 gene contributes to…

M. Michele Blackwood, MD, FACS, Chief, Section of Breast Surgery, Rutgers Cancer Institute of New Jersey, Northern Regional Director of Breast Services, RWJBarnabas Health. In this video, she speaks about the I-SPY2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY).   Description in detail:   I-SPY will compare the efficacy of new medications combined with traditional chemotherapy to the efficacy of standard therapy alone. The goal is to find better treatment regimens for specific subsets based on molecular characteristics (biomarker signatures) of their condition. As with past adaptive trials, regimens that demonstrate a high Bayesian prediction…

M. Michele Blackwood, MD, FACS, Chief, Section of Breast Surgery, Rutgers Cancer Institute of New Jersey, Northern Regional Director of Breast Services, RWJBarnabas Health. In this video, she speaks about the I-SPY2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY).   Description in detail:   I-SPY will compare the efficacy of new medications combined with traditional chemotherapy to the efficacy of standard therapy alone. The goal is to find better treatment regimens for specific subsets based on molecular characteristics (biomarker signatures) of their condition. As with past adaptive trials, regimens that demonstrate a high Bayesian prediction…

Mark Pegram, MD, is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford Cancer Institute. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). He also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine and is the Medical Director of the Stanford Clinical Translational Research Unit – a unit specializing in first-in-human phase I clinical trials. In this video, he speaks about the Miami Breast 2022 Discussion – New Frontiers in Breast Cancer: Targeted Therapy, Immunotherapy, and Combinations.

Mark Pegram, MD, is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford Cancer Institute. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). He also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine and is the Medical Director of the Stanford Clinical Translational Research Unit – a unit specializing in first-in-human phase I clinical trials. In this video, he speaks about the Miami Breast 2022 Discussion – New Frontiers in Breast Cancer: Targeted Therapy, Immunotherapy, and Combinations.

Mehmet Altan, MD, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. In this video, he speaks about Pulmonary Toxicities of Immunotherapy.   Outline Immune checkpoint inhibitors are a type of immunotherapy that is increasingly being employed in the treatment of a wide range of malignancies. Immune-related adverse events (irAEs) offer a significant issue in cancer treatment. Pneumonitis, the most common lung irAE, can cause severe interruptions in cancer treatment and can be fatal. The purpose of this chapter is to inform readers on the occurrence and clinical features of pneumonitis, as well as to…

Mehmet Altan, MD, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. In this video, he speaks about Pulmonary Toxicities of Immunotherapy.   Outline Immune checkpoint inhibitors are a type of immunotherapy that is increasingly being employed in the treatment of a wide range of malignancies. Immune-related adverse events (irAEs) offer a significant issue in cancer treatment. Pneumonitis, the most common lung irAE, can cause severe interruptions in cancer treatment and can be fatal. The purpose of this chapter is to inform readers on the occurrence and clinical features of pneumonitis, as well as to…

Michael Alvarado, MD, Professor of Surgery, Division of Surgical Oncology, Director, Breast Surgery Oncology Fellowship at University of California San Francisco. In this video, he speaks about the Miami Breast 2022 Discussion – How Has Neoadjuvant Therapy Affected Multidisciplinary Management?

Michael Alvarado, MD, Professor of Surgery, Division of Surgical Oncology, Director, Breast Surgery Oncology Fellowship at University of California San Francisco. In this video, he speaks about the Miami Breast 2022 Discussion – How Has Neoadjuvant Therapy Affected Multidisciplinary Management?

Aditya Bardia, MD, MPH, Director of Breast Cancer Research, Mass General Cancer Center,  Attending Physician, Mass General Cancer Center, Associate Professor in Medicine, Harvard Medical School. In this video, he speaks about the Miami Breast 2022 discussion – Emerging Data on Oral Selective Estrogen Receptor Degraders and Other Novel Hormonal Therapies.

Aditya Bardia, MD, MPH, Director of Breast Cancer Research, Mass General Cancer Center,  Attending Physician, Mass General Cancer Center, Associate Professor in Medicine, Harvard Medical School. In this video, he speaks about the Miami Breast 2022 discussion – Emerging Data on Oral Selective Estrogen Receptor Degraders and Other Novel Hormonal Therapies.

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the Miami Breast 2022 Abstract – Medical Crossfire®: PRO vs CON: Breast IORT Is the Preferred Accelerated Breast Treatment Option.   Brief Synopsis:   Intraoperative radiotherapy (IORT) is a form of accelerated partial breast irradiation (APBI) in which radiation therapy is provided to the breast tissue during a lumpectomy for breast cancer in a single dose. The Xoft device (Axxent, Xoft, San Jose, CA) is an IORT device for breast cancer that…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the Miami Breast 2022 Abstract – Medical Crossfire®: PRO vs CON: Breast IORT Is the Preferred Accelerated Breast Treatment Option. Brief Synopsis: Intraoperative radiotherapy (IORT) is a form of accelerated partial breast irradiation (APBI) in which radiation therapy is provided to the breast tissue during a lumpectomy for breast cancer in a single dose. The Xoft device (Axxent, Xoft, San Jose, CA) is an IORT device for breast cancer that uses kilovoltage…

Charles Loprinzi, MD, Regis Professor of Breast Cancer Research, Medical Oncologist at Mayo Foundation for Medical Education and Research at Mayo Clinic. In this video, he speaks about Chemotherapy-Induced Neuropathy: Guidelines and More.

Charles Loprinzi, MD, Regis Professor of Breast Cancer Research, Medical Oncologist at Mayo Foundation for Medical Education and Research at Mayo Clinic. In this video, he speaks about Chemotherapy-Induced Neuropathy: Guidelines and More.

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the Miami Breast 2022 Abstract – The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device.   The study is an observational, prospective, parallel-arm device use study. The study will include 50 participants. The SOZO gadget will be used in the study to examine changes in the participants’ body composition following cancer therapy. The SOZO device…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the Miami Breast 2022 Abstract – The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device.   The study is an observational, prospective, parallel-arm device use study. The study will include 50 participants. The SOZO gadget will be used in the study to examine changes in the participants’ body composition following cancer therapy. The SOZO device…

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), Professor of Surgery (Oncology), Yale University School of Medicine. In this video, she speaks about the discussion at Miami Breast 2022 – How to Get Involved in Clinical Research…and Recognize What Research Is Worthwhile.

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), Professor of Surgery (Oncology), Yale University School of Medicine. In this video, she speaks about the discussion at Miami Breast 2022 – How to Get Involved in Clinical Research…and Recognize What Research Is Worthwhile.

Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU 2022 abstract – CheckMate -214 (Abstracts #307 & #352): Follow-up results showing meaningful survival benefits with Opdivo plus Yervoy amongst intermediate- and poor-risk RCC patients with sarcomatoid features – a population with poor prognosis and limited therapeutic options – as well as quality of life improvements amongst the all-randomized population.

Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU 2022 abstract – CheckMate -214 (Abstracts #307 & #352): Follow-up results showing meaningful survival benefits with Opdivo plus Yervoy amongst intermediate- and poor-risk RCC patients with sarcomatoid features – a population with poor prognosis and limited therapeutic options – as well as quality of life improvements amongst the all-randomized population.

Christopher Cann, MD, Clinical Fellow, Division of Hematology/Oncology, Department of Medicine at Vanderbilt University Medical Center. In this video, he speaks about the IASLC 2022 Abstract – Circulating Tumor DNA Dynamics in Relapsed Small Cell Lung Cancer Are Predictive of Progression-Free and Overall Survival.  Origins: Relapsed small cell lung cancer (SCLC) is difficult to treat, with low overall survival and objective response rates (ORR) (OS). ORR is currently predicted to be 25-50 percent for platinum-sensitive illness and 10-20 percent for platinum-resistant disease, resulting in a short progression-free survival (PFS) of 4-5 months and an OS of less than one year…

Christopher Cann, MD, Clinical Fellow, Division of Hematology/Oncology, Department of Medicine at Vanderbilt University Medical Center. In this video, he speaks about the IASLC 2022 Abstract – Circulating Tumor DNA Dynamics in Relapsed Small Cell Lung Cancer Are Predictive of Progression-Free and Overall Survival.  Origins: Relapsed small cell lung cancer (SCLC) is difficult to treat, with low overall survival and objective response rates (ORR) (OS). ORR is currently predicted to be 25-50 percent for platinum-sensitive illness and 10-20 percent for platinum-resistant disease, resulting in a short progression-free survival (PFS) of 4-5 months and an OS of less than one year…

Stefano Luminari, MD, Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine at Unimore Università degli studi di Modena e Reggio Emilia (UNIMORE). In this video, he speaks about FOLL12: Response-Adapted Maintenance Not Supported in Follicular Lymphoma.   Intent   In patients with follicular lymphoma who had responded to induction immunochemotherapy, we compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction strategy.   Approaches   On the basis of metabolic response and molecular assessment of minimal residual illness, we randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to either standard…

Stefano Luminari, MD, Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine at Unimore Università degli studi di Modena e Reggio Emilia (UNIMORE). In this video, he speaks about FOLL12: Response-Adapted Maintenance Not Supported in Follicular Lymphoma.   Intent   In patients with follicular lymphoma who had responded to induction immunochemotherapy, we compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction strategy.   Approaches On the basis of metabolic response and molecular assessment of minimal residual illness, we randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to either standard RM…

Matthew Smeltzer, Ph.D., MStat, Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis. Dr. Smeltzer and his co-authors Scagliotti Giorgio, Heather Wakelee, Tetsuya Mitsudomi, and Fred R. Hirsch worked on this trial.  In this video, he speaks about the International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.   Outline Overview:   We polled investigators and collected aggregate enrollment data for lung cancer trials around the world before and during the worldwide COVID-19 pandemic to investigate the effects on lung cancer trials.  …

Matthew Smeltzer, Ph.D., MStat, Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis. Dr. Smeltzer and his co-authors Scagliotti Giorgio, Heather Wakelee, Tetsuya Mitsudomi, and Fred R. Hirsch worked on this trial.  In this video, he speaks about the International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.   Outline   Overview:   We polled investigators and collected aggregate enrollment data for lung cancer trials around the world before and during the worldwide COVID-19 pandemic to investigate the effects on lung cancer trials.…

Mark Moasser, MD, Professor, Department of Medicine (Hematology/Oncology) at UC San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center. In this video, he speaks about Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers and Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.

Mark Moasser, MD, Professor, Department of Medicine (Hematology/Oncology) at UC San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center. In this video, he speaks about Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers and Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.

Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she gives her comments on Abstracts for HER2-low MBCC. Approximately half of all initial breast tumors have low-level HER2 expression (HER2-low), characterized as immunohistochemically 1+ or 2+ and no HER2 gene amplification as assessed by in situ hybridization. This low HER2 expression is a possible new target for antibody-drug conjugates (ADCs), which are currently being researched. Little is known regarding the prevalence and prognostic importance of low HER2-expression in metastatic breast cancer…

Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she gives her comments on Abstracts for HER2-low MBCC.   Approximately half of all initial breast tumors have low-level HER2 expression (HER2-low), characterized as immunohistochemically 1+ or 2+ and no HER2 gene amplification as assessed by in situ hybridization. This low HER2 expression is a possible new target for antibody-drug conjugates (ADCs), which are currently being researched. Little is known regarding the prevalence and prognostic importance of low HER2-expression in metastatic breast cancer…

Adam Brufsky, MD, Ph.D., Professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine’s Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women’s Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; the associate director for clinical investigations at UPMC Hillman Cancer Center; and co-director of the Comprehensive Breast Cancer Center at UPMC. In this interview, he comments on HER2-low MBCC.   Approximately half of all initial breast tumors have…

Adam Brufsky, MD, Ph.D., Professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine’s Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women’s Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; the associate director for clinical investigations at UPMC Hillman Cancer Center; and co-director of the Comprehensive Breast Cancer Center at UPMC. In this interview, he comments on HER2-low MBCC. Approximately half of all initial breast tumors have…

Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy & Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. In this video, he speaks about Colorectal Cancer Awareness Month.

Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy & Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. In this video, he speaks about Colorectal Cancer Awareness Month.

Bart Scott, MD, Professor, Transplantation Program, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the Highlights of ASH 2022 – Hematopoietic Stem Cell Transplantation.   Hematopoietic stem cell transplantation (HSCT) is an intravenous infusion of hematopoietic stem cells used to restore blood cell production in individuals with damaged or dysfunctional bone marrow or immune systems. This approach has been utilized to treat a variety of malignant and nonmalignant disorders with increasing frequency during the last half-century.   Cells for HSCT can be taken from the patient (autologous transplant), a sibling or unrelated donor…

Bart Scott, MD, Professor, Transplantation Program, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the Highlights of ASH 2022 – Hematopoietic Stem Cell Transplantation.   Hematopoietic stem cell transplantation (HSCT) is an intravenous infusion of hematopoietic stem cells used to restore blood cell production in individuals with damaged or dysfunctional bone marrow or immune systems. This approach has been utilized to treat a variety of malignant and nonmalignant disorders with increasing frequency during the last half-century.   Cells for HSCT can be taken from the patient (autologous transplant), a sibling or unrelated donor…

Kim Chi, MD, Vice President & Chief Medical Officer of BC Cancer speaks about TITAN: A final analysis with close to four years of follow-up data evaluating Erleada versus placebo in patients with metastatic castration-sensitive prostate cancer receiving hormone therapy (Abstract #11).   RARITAN, N.J. /PRNewswire/ — Janssen Pharmaceutical Inc., Feb. 2, 2021, Johnson & Johnson companies today reported that at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the clinical development program ERLEADA® (apalutamide), the depth of their solid tumor portfolio will be highlighted. The virtual…

Kim Chi, MD, Vice President & Chief Medical Officer of BC Cancer speaks about TITAN: A final analysis with close to four years of follow-up data evaluating Erleada versus placebo in patients with metastatic castration-sensitive prostate cancer receiving hormone therapy (Abstract #11).   RARITAN, N.J. /PRNewswire/ — Janssen Pharmaceutical Inc., Feb. 2, 2021, Johnson & Johnson companies today reported that at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the clinical development program ERLEADA® (apalutamide), the depth of their solid tumor portfolio will be highlighted. The virtual…